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Rett syndrome, a neurodevelopmental disorder that is a leading cause of mental retardation in females, is caused by mutations in the X-linked gene encoding methyl-CpG-binding protein 2 (MeCP2). MECP2 mutations have subsequently been identified in patients with a variety of clinical syndromes ranging from mild learning disability in females to severe mental retardation, seizures, ataxia, and sometimes neonatal encephalopathy in males. In classic Rett syndrome, genotype-phenotype correlation studies suggest that X chromosome inactivation patterns have a more prominent effect on clinical severity than the type of mutation. When the full range of phenotypes associated with MECP2 mutations is considered, however, the mutation type strongly affects disease severity. MeCP2 is a transcriptional repressor that binds to methylated CpG dinucleotides throughout the genome, and mutations in Rett syndrome patients are thought to result in at least a partial loss of function. Abnormal gene expression may thus underlie the phenotype. Discovering which genes are misregulated in the absence of functional MeCP2 is crucial for understanding the pathogenesis of this disorder and related syndromes. Curr Opin 
Rett syndrome genetics
The early observation that Rett syndrome occurred exclusively in females led to the hypothesis that it was due to a dominant mutation on the X chromosome that was lethal in hemizygous males [2] . Since affected females rarely reproduce and familial cases are extremely rare (less than one percent), it took years of research to generate data supporting such a genetic mechanism. Combining the functional data with expression studies, it appears that MeCP2 binds to a multitude of methylated chromosomal sites and modi®es chromatin structure in a way that represses transcription. Additionally, the broad expression pattern of MeCP2 suggests that the protein is essential for chromatin modi®cation/silencing in many tissues. These conclusions, however, are dif®cult to reconcile with the largely neurological phenotype of Rett syndrome. The function of MeCP2, therefore, is likely to be much more complex.
Spectrum of MECP2 mutations and connection to protein function
As a result of sequence analysis of DNA from Rett syndrome cases, 78 unique MECP2 mutations have been identi®ed in exons 3 and 4 of the gene, which contain a majority of the coding region ( Fig. 1 [28] . Therefore, the possibility still exists that premature stop codons within exon 4 may produce a truncated form of the protein that retains partial function. A truncated protein that retains the MBD, for instance, may still be able to bind to methylCpG nucleotides and may, by virtue of solely binding upstream of potential promoter regions, at least partially interfere with transcription. Whether Rett syndrome is caused by both null and hypomorphic alleles remains an interesting question.
Missense mutations have been identi®ed in regions of the gene encoding the MBD, TRD, and C-terminus of the protein (Fig. 1) . Three of the mutations within the MBD (R106W, R133C, and F155S) have been shown to reduce binding to methylated DNA by more than 100-fold [29 . ]. It remains to be shown whether missense mutations in the TRD reduce interactions with the Sin3A complex and whether mutations in the Cterminus, which enhances the binding of MeCP2 to nucleosomal DNA [30] , decrease interactions with components of the nucleosome.
Phenotypic spectrum of MECP2 mutations
Since the MECP2 gene is X-linked and subject to X chromosome inactivation (XCI) [31] , one would expect XCI patterns to have a potent in¯uence on phenotype. Indeed, it has long been recognized that in addition to classic Rett syndrome, there are milder forms of the syndrome that lack certain signs [1], as well as very severe forms that lack the period of normal development and cause hypotonia and infantile spasms [32] . As more mutation analysis is performed, the classi®cation of these different clinical entities as variants of one syndrome is now being veri®ed at a genetic level [33] . In fact, it is becoming evident that MECP2 mutations produce an even wider range of phenotypes than previously suspected (Table 1) .
Two of the most interesting ®ndings about the variability of clinical features resulting from MECP2 mutations have come from the analysis of familial cases of RTT, four of which have been described. Four members of one family bore the 803delG mutation: a female with mild neurological and learning de®cits and skewed XCI, her daughter and sister with RTT, and her son with neonatal encephalopathy, who died at seventeen months [18 . ]. In a second family, an asymptomatic mother with completely skewed XCI, her daughter with RTT, and her son with neonatal encephalopathy all shared the T158M mutation [34] . Although DNA was not available from another boy who died neonatally, the R168X mutation was found in his three sisters with RTT and in his normal mother with skewed XCI [18 . ]. In a fourth family, the R106W mutation was identi®ed in one sister and a half-sister of a boy with neonatal encephalopathy, for whom DNA was not obtained, but not in their normal mother, presumed to be germline mosaic [11 . ]. Although the MECP2 mutation was con®rmed in only two of the four male neonatal encephalopathy cases, it appears that the same mutations that cause classic Rett syndrome in females can also cause neonatal encephalopathy in males, whereas females can be spared part or all of the neurological impairments through skewed XCI. Although it is possible that cells expressing mutant MeCP2 are selected against, this seems unlikely, since the same mutation occurs in carrier females and in their affected daughters. Therefore, the skewed XCI pattern in carrier females is likely to be due to chance. X487C   P322A  P322L  R306C  R306H  P302A  P302H  P302L  P302R  P225R   T158M   D156E  F155I  F155S   P152R  A140V*   S134C  R133C   L124F   P101H  P101L  P101R  P101T  D97E   Coding   Untranslated   MBD   TRD   1159del43 seizures, decreased head circumference, scoliosis, and ataxia. Mutation analysis showed that this male probably survived due to somatic mosaicism for a MECP2 mutation (167-168delCC), such that some of his cells had the mutant allele and some had a wild-type allele, much like females with random X chromosome inactivation.
Genotype-phenotype correlations in Rett syndrome and related disorders
To determine whether different types of mutations in MECP2 can account for the variability of phenotypes in Rett syndrome, several groups have conducted genotypephenotype correlation studies. Amir et al. studied patients with balanced XCI and classi®ed the genotypes as either missense or truncation mutations; they found no correlation between genotype and overall clinical severity score but did detect increased respiratory abnormalities and decreased cerebrospinal¯uid levels of homovanillic acid in patients with truncations and increased incidence of scoliosis in patients with missense mutations . It thus appears that in classic Rett syndrome, the correlation between mutation type and phenotype is minimal, with XCI being a major determinant of clinical manifestations.
There appears to be a stronger correlation between genotype and phenotype when neurological disorders other than Rett syndrome are considered. Two groups have screened cases of X-linked mental retardation for mutations. Orrico et al. [36 . ] found an A140V mutation in four brothers with severe mental retardation and in their mother and sister, who had mild mental retardation, microcephaly, speech dif®culties, and gait abnormalities. Since these males survived into adulthood and the females had balanced XCI patterns [36 . ], this mutation may impair the function of MeCP2 less than those causing Rett syndrome. In another study, Meloni et al. [37 . ] found that two mentally retarded males had a Q406X mutation, which was also shared by two unaffected carrier females ± who, unexpectedly, showed balanced XCI patterns. The two males had delayed development and macrocephaly, but, like Rett patients, also displayed seizures, ataxia, and absence of language [37 . ]. Since the males survived into adulthood and the females were normal despite balanced XCI, this mutation may be less deleterious to MeCP2 function than the A140V mutation and much less than the mutations causing Rett syndrome.
Pathogenesis of Rett syndrome
In view of the extensive binding pattern of MeCP2 on chromosomes, how does one explain the neuronal speci®city of Rett syndrome? One possibility might be that the higher levels of MeCP2 detected in the brain [12] , particularly the hippocampus [17], signify areas where MeCP2 function is uniquely essential. This would imply that binding of MeCP2 to most methylated chromosomal regions is dispensable since, if binding of MeCP2 were indeed essential in every methylated region, the consequence of its loss would be equivalent to loss of methylation. Yet this is not the case: extensive demethylation of the mouse genome by mutation of DNA methyltransferase 1 (Dnmt1) is embryonic-lethal [38] , whereas mutation of the murine Mecp2 gene is not [39] . Furthermore, mutations of another DNA methyltransferase, DNMT3B, in humans leads to a syndrome characterized by immunode®ciency, centromere instabil- ity and facial anomalies (ICF) [40, 41] . In ICF syndrome, genomic methylation is only partially lost, primarily in satellites II and III of constitutive heterochromatin of chromosomes 1, 9, and 16 [41] . Since the phenotype of Rett syndrome does not include features of ICF, it appears that MeCP2 is not essential for mediating the effects of methylation of even this small subset of methylated DNA. In addition, the fact that Dnmt3b-de®cient mice, which have hypomethylated minor satellite repeats in centromeric heterochromatin, also die before birth [42] provides convincing evidence for the dispensability of MeCP2 binding in these regions. MeCP2 binding may be essential only for repressing expression of a select group of genes, although the mechanism that might account for this is dif®cult to predict. These genes may be neuronal-speci®c or widely expressed but detrimental only to neuronal development when misexpressed. In support of the idea that MeCP2 might regulate only a subset of genes, the CpG islands associated with the promoters of most genes are nonmethylated, and only a subset of genes are known to be regulated by methylation (e.g., those that are either imprinted or undergo inactivation on the X chromosome). There is a tight correlation in various cell types between methylation and silencing as well as nonmethylation and expression for some genes that are regulated in a tissue-speci®c manner, such as leukosialin (CD43) [43] . Although the cause-and-effect relationship is dif®cult to prove, it is certainly possible that methylation patterns are responsible for the tissuespeci®c expression of some genes. For genes that may be methylated in neurons and silenced by MeCP2, the mutated protein could allow inappropriate expression and thereby disrupt neuronal development.
It is worth noting that MeCP2 is a member of a growing family of MBD-containing proteins [44] . Like MeCP2, MBD1 has been shown to act as a transcriptional repressor and to localize to centromeric heterochromatin [45] . Another family member, MBD2, also represses transcription in vitro and, along with MBD4, colocalizes with regions of methylated satellite DNA [44, 46] . With the high level of functional similarity between these proteins, it is possible that these or other comparable proteins could substitute for at least the broad, chromatin-binding role of MeCP2. Notably, no other MBD-containing protein has been shown to have as high af®nity for methyl-CpG dinucleotides as MeCP2, which can bind just a single symmetrical pair [12] . Therefore, MeCP2 may be the only family member that can silence genes regulated by low methylation density, and it may be misexpression of these genes that underlies the Rett syndrome phenotype.
Another aspect of the Rett syndrome phenotype that is dif®cult to reconcile with the expression pattern of MeCP2 is the delay in the onset of overt features. One possible explanation is that the genes repressed by MeCP2 do not become methylated until later in development. Several neuronal gene promoters have, in fact, been found to undergo a developmental change in methylation. With restriction landmark genomic scanning using methylation-sensitive endonuclease (RLGS-M), Suzuki et al. [47] showed that Stac, a gene expressed primarily in brain (and at highest levels in the hippocampus, cerebellum, and inferior olive), displays a developmental change in methylation pattern in the mouse brain. In addition, the glial ®brillary acidic protein (GFAP) gene undergoes methylation during neuronal maturation in the rat brain [48] . Furthermore, when inducing differentiation with nerve growth factor, the expression of genes encoding the helix-loop-helix proteins Id1, Id2, and Id3 was reduced, but only in the presence of DNA methyltransferase activity [49] . All these examples demonstrate that neuronal maturation may require changes in expression of genes mediated by DNA methylation. Any of these genes, or other similarly regulated genes, could be targets of MeCP2 repression.
Conclusion
The discoveries that the MECP2 gene was mutated in Rett syndrome and in non-syndromic forms of mental retardation provide a great advance in clinical neurology. Patients with features resembling Rett syndrome, nonsyndromic mental retardation, and neonatal encephalopathy of unknown etiology can now be evaluated for MECP2 mutations. Genetic counseling can be offered to families with carrier females to reduce the risk of recurrence. It remains to be determined why mutation of the widely expressed MECP2 gene leads to a neuronal phenotype, what genes are regulated by MeCP2, and how mutations in MECP2 give rise to the characteristic features of Rett syndrome. When suitable animal models become available, addressing these perplexing issues will be possible. 
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